Magnetic resonance imaging and pyramidal impairment in Huntington disease
Objective: To identify structural involvement of the corticospinal pathway in Huntington disease (HD) with clinical upper motor neuron signs using diffusion tensor imaging (DTI). Background:…Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the FIRST-HD and TETRA-HD trials
Objective: To compare the tolerability of deutetrabenazine (DTB) and tetrabenazine (TBZ) as observed in the FIRST-HD (NCT01795859) and TETRA-HD (NCT00219804) trials for the treatment of…Clinical and behavioral features in carriers of intermediate length alleles of HTT gene. A case series of Mexican population
Objective: To describe clinical manifestations in carriers of intermediate alleles (IAs) of CAG trinucleotides in HTT gene of Mexican population. Background: Huntington's disease (HD) is…Prospective evaluation of pallidal deep brain stimulation in Huntington’s disease
Objective: To prospectively evaluate the effect of bilateral pallidal deep brain stimulation (DBS) on motor symptoms, activities of daily living and quality of life in…CAG repeat length and weight loss in pre-manifest Huntington’s disease
Objective: To explore if CAG repeat length is a predictor of weight loss in pre-manifest Huntington's disease. Background: Weight loss is a hallmark finding in…Temporal course of the UHDRS chorea score in Huntington disease
Objective: To describe the temporal course of Huntington disease (HD) chorea using the total maximal chorea score of the Unified Huntington Disease Rating Scale -…Psychosis in Huntington’s disease
Objective: To describe the characteristics and phenomenology of psychotic symptoms in a Spanish cohort of HD patients. Background: Neuropsychiatric features are characteristic symptoms in Huntington's…Functional motor outcomes after globus pallidus internus deep brain stimulation in Huntington´s disease – A case report
Objective: The aim of this study was to analyse the motor outcome before and after 6 month follow-up in a HD patient treated by GPi-DBS.…A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval
Objective: Evaluate the pharmacokinetics and pharmacodynamics (QTc) of SD-809 (deutetrabenazine) and tetrabenazine. Background: SD-809 is a VMAT-2 inhibitor in clinical development for treatment of hyperkinetic…Temporal course of the total motor score in Huntington disease
Objective: To describe the temporal course of motor features in Huntington disease (HD) using the Unified Huntington Disease Rating Scale - Total Motor Score (UHDRS-TMS)…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 11
- Next Page »